{
    "abstract": [],
    "body_text": [
        {
            "text": "Infectious adverse events after transrectal prostate biopsy (TPBX) have been increasing, and even septic and fatal cases have been reported [1,2]. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 140,
                    "end": 143,
                    "type": "bibr",
                    "ref_id": "b0",
                    "text": "[1,"
                },
                {
                    "start": 143,
                    "end": 145,
                    "type": "bibr",
                    "ref_id": "b1",
                    "text": "2]"
                }
            ]
        },
        {
            "text": "Fluoroquinolones have long been used for prophylactic administration owing to their good efficacy and high concentration in the prostate after dosing. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "However, especially in urinary tract infections (UTIs), fluoroquinolone-resistant Escherichia coli (FQRE) has been rapidly increasing. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 99,
                    "end": 105,
                    "type": "bibr",
                    "text": "(FQRE)"
                }
            ]
        },
        {
            "text": "Resistance ratios to levofloxacin (LVFX) have jumped up to 5% to 20% [3]. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 69,
                    "end": 72,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "[3]"
                }
            ]
        },
        {
            "text": "Because TPBX is increasingly used to detect prostate cancer, adverse events are a growing concern [2]. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 98,
                    "end": 101,
                    "type": "bibr",
                    "ref_id": "b1",
                    "text": "[2]"
                }
            ]
        },
        {
            "text": "Intravenous antibiotics should be considered, partly for preventing septic cases as mentioned above. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "Another resistant strain, extended-spectrum beta-lactamase (ESBL)-producing E. coli, also poses difficulties for treatment. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "Some kinds of carbapenems are available for this resistant strain, but it has the potential to be an intractable infection. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "Some authors previously reported a case of prostatitis caused by ESBL-producing E. coli and it could be treated by imipenem and tazobactam/piperacillin (TAZ/PIPC) [4]. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 163,
                    "end": 166,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "[4]"
                }
            ]
        },
        {
            "text": "Beta-lactamase inhibitors have generally been combined with penicillins partly because this combination can bring out the antibiotic activity fully and prevent the emergence of antibiotic-resistant strains [5]. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 206,
                    "end": 209,
                    "type": "bibr",
                    "ref_id": "b4",
                    "text": "[5]"
                }
            ]
        },
        {
            "text": "TAZ/PIPC (Zosin \u00ae ) is an intravenous antibiotic agent consisting of 4 g of piperacillin and 0.5 g of tazobactam at an 8:1 ratio and is a modification of Tazosin \u00ae , which was used before and consisted of 2 g of piperacillin and 0.5 g of tazobactam [5,6]. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 162,
                    "end": 163,
                    "type": "bibr",
                    "text": "\u00ae"
                },
                {
                    "start": 249,
                    "end": 252,
                    "type": "bibr",
                    "ref_id": "b4",
                    "text": "[5,"
                },
                {
                    "start": 252,
                    "end": 254,
                    "type": "bibr",
                    "ref_id": "b5",
                    "text": "6]"
                }
            ]
        },
        {
            "text": "Penicillins combined with beta-lactamase inhibitors such as TAZ/PIPC are widely used to treat UTIs and show good efficacy for E. coli, including FQRE and ESBL-producing E. coli, and are recommended for TPBX in the Japanese UTI association guidelines especially in high risk group [7]. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 280,
                    "end": 283,
                    "type": "bibr",
                    "ref_id": "b6",
                    "text": "[7]"
                }
            ]
        },
        {
            "text": "In this study, we examined whether TAZ/ PIPC plus LVFX could suppress infectious adverse events after TPBX.",
            "section": "INTRODUCTION"
        },
        {
            "text": "We performed a study of 201 consecutive men scheduled for TPBX because of an elevated prostate-specific antigen (PSA) level, an abnormal digital rectal examination (DRE), or abnormal magnetic resonance imaging (MRI) or transrectal ultrasound (TRUS) findings. ",
            "section": "Prostate biopsy"
        },
        {
            "text": "TPBXs were performed in Akashi Municipal Hospital from March 2009 to September 2010. ",
            "section": "Prostate biopsy"
        },
        {
            "text": "All biopsies were performed with an 18-gauge Bard Max Core disposable biopsy instrument biopsy needle (C.R. Bard Inc., Convington, GA, USA) in conjunction with a medical ultrasound console (Aloka SSD-2000, Aloka Co. Ltd., Tokyo, Japan). ",
            "section": "Prostate biopsy"
        },
        {
            "text": "Acetylsalicylic acid or oral anticoagulant agents were stopped appropriately before TPBX with the approval of the prescribing physician as a rule. ",
            "section": "Prostate biopsy"
        },
        {
            "text": "We took 8 (sextant\uff0b2 transitional zone) cores. ",
            "section": "Prostate biopsy"
        },
        {
            "text": "No preparatory cleansing enemas were used, and the TPBX procedure was performed with only sacral anesthesia with 1% lidocaine and povidone iodine sterilization just before the TPBX.",
            "section": "Prostate biopsy"
        },
        {
            "text": "For prophylactic antibiotic medication, each patient received TAZ/PIPC 4.5 g i.v. and LVFX 100 mg or 500 mg taken orally 30 minutes before TPBX. ",
            "section": "Prophylactic antibiotic administration"
        },
        {
            "text": "Patients continued to take 100 mg after every meal or 500 mg LVFX once a day for 3 days with or without styptic or anti-plasmin. ",
            "section": "Prophylactic antibiotic administration"
        },
        {
            "text": "The dose of LVFX was changed to 500 mg from 300 mg per day from August 2009 in this study. ",
            "section": "Prophylactic antibiotic administration"
        },
        {
            "text": "Another TAZ/PIPC was given 3 hours after TPBX. ",
            "section": "Prophylactic antibiotic administration"
        },
        {
            "text": "Patients were examined for infectious adverse events after TPBX and white blood cell (WBC) counts (/mm 3 ) and C-reactive protein (CRP) (\u03bcg/ml) in plasma were measured before and 1 day after TPBX. ",
            "section": "Prophylactic antibiotic administration",
            "ref_spans": [
                {
                    "start": 103,
                    "end": 104,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "3"
                }
            ]
        },
        {
            "text": "All patients undergoing TPBX were hospitalized on the day of TPBX and were discharged the next day if there were no adverse events requiring further hospitalization. ",
            "section": "Prophylactic antibiotic administration"
        },
        {
            "text": "The day after TPBX, patients' laboratory data were checked including WBC and CRP in serum. ",
            "section": "Prophylactic antibiotic administration"
        },
        {
            "text": "If a patient had symptoms from infectious complications such as chills or fever greater than 38.0 o C after TPBX, he was asked to return to the emergency department. ",
            "section": "Prophylactic antibiotic administration"
        },
        {
            "text": "He immediately underwent a urinalysis, urine culture, and blood analysis, and any other complica-tions were recorded. ",
            "section": "Prophylactic antibiotic administration"
        },
        {
            "text": "As a rule, if acute prostatitis was diagnosed, the patient was hospitalized and treated with the third-or fourth-generation cephalosporin or carbapenem i.v., and blood and urine culture tests were performed. ",
            "section": "Prophylactic antibiotic administration"
        },
        {
            "text": "Patient data are shown in Table 1. ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 26,
                    "end": 33,
                    "type": "table",
                    "text": "Table 1"
                }
            ]
        },
        {
            "text": "One of 201 patients (0.50%) had a febrile complication such as acute prostatitis after TPBX. ",
            "section": "RESULTS"
        },
        {
            "text": "Our data from laboratory tests done the day after TPBX, including serum WBC count and CRP, did not demonstrate a significant rise in these variables compared with the pre-TPBX data as shown in Table 2 (p\uff1e0.05). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 193,
                    "end": 200,
                    "type": "table",
                    "text": "Table 2"
                }
            ]
        },
        {
            "text": "The serum WBC count before and after TPBX (day 1) was 6,123 \u00b11,655 and 6,427\u00b11,898 (/mm 3 ), respectively. ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 88,
                    "end": 89,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "3"
                }
            ]
        },
        {
            "text": "Serum CRP before and after TPBX (day 1) was 0.1702\u00b10.4020 and 0.2602\u00b10.4534 (\u03bcg/ml), respectively ( Table 2). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 100,
                    "end": 108,
                    "type": "table",
                    "text": "Table 2)"
                }
            ]
        },
        {
            "text": "No patients showed obvious side effects from this regimen (TAZ/PIPC plus LVFX).",
            "section": "RESULTS"
        },
        {
            "text": "A case with febrile complication had fever (37.6 o C) from the night of TPBX and his serum WBC and CRP rose up (18,100/mm 3 and 4.1 \u03bcg/ml, respectively) on the next day. ",
            "section": "RESULTS"
        },
        {
            "text": "He had dysuria and was diagnosed as having acute prostatitis. ",
            "section": "RESULTS"
        },
        {
            "text": "He was treated by i.v. doripenem 0.5 g/day and his symptoms and laboratory data reacted very well and improved. ",
            "section": "RESULTS"
        },
        {
            "text": "His urine culture test on the day after TPBX showed no growth of bacteria. ",
            "section": "RESULTS"
        },
        {
            "text": "His TPBX pathological result was prostate cancer. ",
            "section": "RESULTS"
        },
        {
            "text": "In addition, we compared LVFX 500 mg with LVFX 300 mg in the TAZ/PIPC plus LVFX regimen; however, there were no significant differences between the two groups re-  (Table 3).",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 164,
                    "end": 173,
                    "type": "table",
                    "ref_id": "tab_2",
                    "text": "(Table 3)"
                }
            ]
        },
        {
            "text": "Prostate biopsies can cause infectious adverse events, especially with the transrectal approach [8]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 96,
                    "end": 99,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "[8]"
                }
            ]
        },
        {
            "text": "TPBX is a test for the detection of prostate cancer and most patients have cancer-negative results in general [9]; therefore, severe adverse events must be prevented. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 110,
                    "end": 113,
                    "type": "bibr",
                    "ref_id": "b8",
                    "text": "[9]"
                }
            ]
        },
        {
            "text": "Recently, the ratio of infectious complications after TPBX has risen and even septic or fatal cases have been reported [1,2]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 119,
                    "end": 122,
                    "type": "bibr",
                    "ref_id": "b0",
                    "text": "[1,"
                },
                {
                    "start": 122,
                    "end": 124,
                    "type": "bibr",
                    "ref_id": "b1",
                    "text": "2]"
                }
            ]
        },
        {
            "text": "One of the main reasons for this unfortunate fact is the increase of antibiotic-resistant Enterobacteriaceae [10,11]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 109,
                    "end": 113,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "[10,"
                },
                {
                    "start": 113,
                    "end": 116,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "11]"
                }
            ]
        },
        {
            "text": "Naturally, E. coli is one of the main targets to suppress in this procedure, and infectious adverse events may be partly caused by antibiotic-resistant bacteria [1,4].",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 161,
                    "end": 164,
                    "type": "bibr",
                    "ref_id": "b0",
                    "text": "[1,"
                },
                {
                    "start": 164,
                    "end": 166,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "4]"
                }
            ]
        },
        {
            "text": "Fluoroquinolones are often used for prophylactic medication in TPBX, partly because they are retained at high concentrations in the prostate as mentioned above [12,13]; however, fluoroquinolone-resistant E. coli are spreading, especially in UTI [3]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 160,
                    "end": 164,
                    "type": "bibr",
                    "ref_id": "b11",
                    "text": "[12,"
                },
                {
                    "start": 164,
                    "end": 167,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13]"
                },
                {
                    "start": 245,
                    "end": 248,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "[3]"
                }
            ]
        },
        {
            "text": "A guideline for prophylactic antibiotic medication for TPBX in 2006 and 2007 recommends fluoroquinolones in low-risk groups and TAZ/PIPC in high-risk groups [7,14]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 157,
                    "end": 160,
                    "type": "bibr",
                    "ref_id": "b6",
                    "text": "[7,"
                },
                {
                    "start": 160,
                    "end": 163,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "14]"
                }
            ]
        },
        {
            "text": "However, infectious complications and septic cases after TPBX increased after the publication of this guideline [15]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 112,
                    "end": 116,
                    "type": "bibr",
                    "ref_id": "b14",
                    "text": "[15]"
                }
            ]
        },
        {
            "text": "Our regimen was set for the following reasons: ",
            "section": "DISCUSSION"
        },
        {
            "text": "1) good efficacy of TAZ/PIPC for E. coli including beta-lactamase-producing bacteria, ",
            "section": "DISCUSSION"
        },
        {
            "text": "2) good intra-prostate concentrations and permeability of LVFX, ",
            "section": "DISCUSSION"
        },
        {
            "text": "3) the data on TAZ/PIPC alone mentioned below, and ",
            "section": "DISCUSSION"
        },
        {
            "text": "4) the higher resistance ratio of E. coli to LVFX in our previous study (data not shown) than before [3], and ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 101,
                    "end": 104,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "[3]"
                }
            ]
        },
        {
            "text": "5) the higher ratio of ESBL-producing E. coli among all E. coli isolated recently than before in our institution (data not shown). ",
            "section": "DISCUSSION"
        },
        {
            "text": "Guidelines need to be updated to reflect the current antibiotic susceptibilities of emergent bacterial strains [16]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 111,
                    "end": 115,
                    "type": "bibr",
                    "ref_id": "b15",
                    "text": "[16]"
                }
            ]
        },
        {
            "text": "As reported in the literature, the ratios of febrile infectious complications range from 0.51% to 7.27% [2,8,17], which suggests that our method could be one of the recommendations for this purpose. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 104,
                    "end": 107,
                    "type": "bibr",
                    "ref_id": "b1",
                    "text": "[2,"
                },
                {
                    "start": 107,
                    "end": 109,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "8,"
                },
                {
                    "start": 109,
                    "end": 112,
                    "type": "bibr",
                    "ref_id": "b16",
                    "text": "17]"
                }
            ]
        },
        {
            "text": "In addition, our previous method [LVFX plus aminoglycoside (isepamicin)] has shown good efficacy for this purpose [8]; however, partly because of the spread of resistant strains, the previous method should be reconsidered and revised by the current data. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 114,
                    "end": 117,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "[8]"
                }
            ]
        },
        {
            "text": "For instance, Kato et al reported a case of septic shock caused by fluoroquinolone-resistant E. coli after TPBX [15], and Carlson et al re-ported multi-drug-resistant E. coli urosepsis cases including a death case following TPBX [18]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 112,
                    "end": 116,
                    "type": "bibr",
                    "ref_id": "b14",
                    "text": "[15]"
                },
                {
                    "start": 229,
                    "end": 233,
                    "type": "bibr",
                    "ref_id": "b17",
                    "text": "[18]"
                }
            ]
        },
        {
            "text": "In addition, Kim et al reported 923 cases of TPBX and concluded that almost cases of acute prostatitis (2.0%) were caused by fluoroquinolone-resistant E. coli [19]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 159,
                    "end": 163,
                    "type": "bibr",
                    "ref_id": "b18",
                    "text": "[19]"
                }
            ]
        },
        {
            "text": "This may suggest that the trend in infection and resistant strains could change and should be monitored and the guidelines revised if necessary.",
            "section": "DISCUSSION"
        },
        {
            "text": "Regarding antibiotic-resistant E. coli, ESBL-producing E. coli have been reported as problematic to treat even in UTIs as mentioned above [20,21]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 138,
                    "end": 142,
                    "type": "bibr",
                    "ref_id": "b19",
                    "text": "[20,"
                },
                {
                    "start": 142,
                    "end": 145,
                    "type": "bibr",
                    "ref_id": "b20",
                    "text": "21]"
                }
            ]
        },
        {
            "text": "Lee et al reported the prevalence of ESBL-producing uropathogens in UTI patients, and the overall prevalence ratio was 12.6% in their 3-year study [22]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 147,
                    "end": 151,
                    "type": "bibr",
                    "ref_id": "b21",
                    "text": "[22]"
                }
            ]
        },
        {
            "text": "This trend is apparently growing and raises some doubt as to whether we can decrease the dose of TAZ/PIPC or LVFX for future's study. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Our laboratory data for serum WBC and CRP demonstrate that our regimen offers good efficacy for suppressing inflammation and infectious adverse events after TPBX. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Our ratio of infectious complications after TPBX was 0.50%, indicating its suitability even for high-risk patients. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Our next step will, as mentioned above, be to consider reducing the dose of TAZ/ PIPC and LVFX to once each on the day of TPBX (just before the procedure) for low-risk patients, while strictly monitoring for resistant strains. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Some authors report the efficacy of oral antibiotics for this purpose, but it might be necessary to combine intravenous antibiotics for suppression of septic cases. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Because TPBX detects prostate cancer in only 20% to 30% of cases, and because most of these patients have organ-confined cancer that may not cause early death [8,23], serious complications from the diagnostic procedure itself should be regarded as unacceptable as mentioned above. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 159,
                    "end": 162,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "[8,"
                },
                {
                    "start": 162,
                    "end": 165,
                    "type": "bibr",
                    "ref_id": "b22",
                    "text": "23]"
                }
            ]
        },
        {
            "text": "Our results of only one febrile complication in 201 consecutive cases and no influence on infection-related laboratory data (WBC and CRP) support an updated methodology for prophylactic medication. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Guidelines need to be updated regularly, because long repetition of a single recommendation may lead to widespread emergence of resistant bacterial strains. ",
            "section": "DISCUSSION"
        },
        {
            "text": "In general, more than two different regimens should be offered. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Our data definitely showed a lower infectious complication ratio after TPBX, even though direct comparison could not be done because of the difference in core number, compared with the regimen of TAZ/PIPC alone (13.5 g per day, once daily) as used in Kobe University Hospital [7/180: 3.89% in 10 (sextant\uff0b2 transitional zone\uff0b2 far lateral periphe-ral zone) cores; data not shown]. ",
            "section": "DISCUSSION"
        },
        {
            "text": "In addition, the data analyzed to observe an effect of LVFX dosing (300 mg or 500 mg per day as shown in Table 3) suggested that our TAZ/ PIPC plus LVFX protocol was not affected by LVFX doses.",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 105,
                    "end": 112,
                    "type": "table",
                    "ref_id": "tab_2",
                    "text": "Table 3"
                }
            ]
        },
        {
            "text": "In addition, the TPBX cases from Kobe University Hospital reported here included low-risk patients because the data were from consecutive TPBX cases. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Moreover, our previous regimen and study [8] was performed from 2003 to 2008, and the high prevalence of ESBL-producing E. coli was reported from the study done from 2007 to 2009 [22]. ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 41,
                    "end": 44,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "[8]"
                },
                {
                    "start": 179,
                    "end": 183,
                    "type": "bibr",
                    "ref_id": "b21",
                    "text": "[22]"
                }
            ]
        },
        {
            "text": "Taken together, these data suggest that our current regimen could be considered as one of the recommendations for not only high-risk patients but also non-high-risk patients.",
            "section": "DISCUSSION"
        },
        {
            "text": "Even though we showed good efficacy, this study may have limitations and further comparison study with the same patient group, study period, and method may be required. ",
            "section": "DISCUSSION"
        },
        {
            "text": "This single-arm study was also performed to confirm not only the effect of this regimen but also the safety for patients without any severe side effects.",
            "section": "DISCUSSION"
        },
        {
            "text": "TAZ/PIPC plus fluoroquinolones can be considered a valuable prophylactic regimen for preventing infectious complications in TPBX. ",
            "section": "CONCLUSIONS"
        },
        {
            "text": "TAZ/PIPC plus fluoroquinolones is one of the options for prophylactic antimicrobial administration in TPBX, especially in high-risk groups.",
            "section": "CONCLUSIONS"
        },
        {
            "text": "We thank Dr. Kunito Yamanaka for taking care of the patients and Gary Mawyer M.F.A. for English editing.",
            "section": "ACKNOWLEDGEMENTS"
        },
        {
            "text": "The authors have nothing to disclose.",
            "section": "Conflicts of Interest"
        }
    ]
}